Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. - sprookjes - yvandenbroek - TriplyDB

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

http://www.wikidata.org/entity/Q33380002

about

The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for hum Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma Current and emerging therapies in unresectable and recurrent gastric cancer Advanced gastric cancer: Current treatment landscape and future perspectives Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.Hepatoid adenocarcinoma of the stomach – a different histology for not so different gastric adenocarcinoma: a case report Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer.Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.Quality of life in the trastuzumab for gastric cancer trial Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis.Targeted therapies for gastric cancer: current status.Capecitabine in gastric cancer.Recent advances in chemotherapy for advanced gastric cancer Standard First-Line Chemotherapy for Metastatic Gastric Cancer in Japan Has Met the Global Standard: Evidence From Recent Phase III Trials.A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Treatment options in patients with metastatic gastric cancer: current status and future perspectives Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis.Recent advances in the HER2 targeted therapy of gastric cancer Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer.Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis.A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy.Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Impact of the availability of active cytotoxic agents on the survival of patients with advanced gastric cancer Seom guidelines for the treatment of gastric cancer 2015.

P2860

Q24633301-0BBCF107-0B19-4905-9299-29CE14CB23C2 Q26741530-53A03237-3134-42C2-8CFF-E74FEB426E09 Q26745453-587CCCFA-0A08-4843-BA80-AF637EC78BB7 Q26764934-232CC6A2-1E46-43C3-8B28-39080785D7A2 Q26798420-17C04AC7-CD75-4441-AEA0-1052825DFA61 Q27318805-7CE9AA61-AA69-4ED2-8917-FA2BE8F54847 Q27497441-9F43FFF1-E4C2-46C4-BF75-5F4DC20C658E Q28077666-20C1C267-CA47-44BF-84EC-CA0423DF024F Q28079750-48F65164-9207-47AB-BEA1-EC5B3E4CA3AA Q28084888-DCCB39C4-23EE-48AC-8755-BD76CB3FEFB7 Q28544422-92180F92-FFF8-4554-89D2-5C76AB44768D Q33383287-F250197D-7412-48B9-970A-11AD975B095C Q33393276-0F1D8318-B958-4306-8AE8-04BB0A358468 Q33402388-F447BB4C-FFF6-42FA-865C-44348D6F0798 Q33416115-02893F2D-1A82-47DB-A01E-C543C6C9E433 Q33560114-FEBF1472-DDD8-4E84-BE8A-57DF101F0772 Q33594906-9A0D4610-03F7-472A-80F4-4241E4FB6934 Q33658636-905E1E1D-4BE9-477C-8A15-9B951C45704E Q33783293-E39F2225-2605-44DE-83C8-7B242528FF4B Q33829785-FF5B9896-A7BF-4666-ABC1-0CA90724CFAD Q33889328-EE516F20-DF6D-4769-B3F5-9C67C2A23E5A Q34205672-5AC091AA-D097-4C17-9F59-F02C3048BF2E Q34236005-D388F573-F821-4598-8319-37AE418A8EAD Q34389753-6767ED58-1DBB-47F5-9703-866D9CFB474D Q34395983-46AC4529-B109-4E6F-AD4E-25BE77626FE4 Q34609932-CC59A5A4-A347-4336-AB4F-76679E299B11 Q34620678-E8AC729A-BAD7-4125-BE14-0A0AD176205B Q34656353-241A6F6F-14BA-4ACA-8FB5-D81E920C3228 Q34661367-E8BD6A27-DB55-42A3-9F51-74D2A433AC67 Q34669648-3FB2F6F6-3D8B-495D-8EF6-4B8395BFBDDE Q34852173-E7A5EC97-9376-4A42-9249-39537DC454A0 Q34967104-9B13F1CA-28EB-41E5-A22B-765CE7B82AC5 Q35051856-A870DCE8-F2F1-49BC-9B47-7CA0E9430F42 Q35076251-58330380-1F71-43B1-9F00-C3DA8435B17B Q35080136-4B43714D-1A66-44A8-A2FA-0BCF3F87B10A Q35612770-8B8A2B64-352F-4438-AEE1-14BA084B8471 Q35753663-4B9E4C55-58EA-4B08-AB6B-33216FDAEF7B Q35863874-70889A04-B079-4901-889D-CE6115AA5F90 Q36085937-098349AB-BE68-4AE4-AA09-45F6831A7306 Q36400378-B889692D-FBF2-4DAB-A052-1F29532C58A3

P2860

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

http://www.wikidata.org/entity/Q33380002

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Randomized phase III study com ...... h or esophagogastric junction.

@ast

Randomized phase III study com ...... h or esophagogastric junction.

@en

type

label

Randomized phase III study com ...... h or esophagogastric junction.

@ast

Randomized phase III study com ...... h or esophagogastric junction.

@en

prefLabel

Randomized phase III study com ...... h or esophagogastric junction.

@ast

Randomized phase III study com ...... h or esophagogastric junction.

@en

P1433

Q33380002-6BE06381-DCDB-4C85-8608-BEF7FC257BB1

P1476

Q33380002-23A12E21-7E36-4A98-93E2-2F0B49780378

P2093

Q33380002-01C65E27-4766-45C8-B76A-101AA37FCC39

Q33380002-304DBD74-28C4-40C5-B66C-57EBEF3225AF

Q33380002-3F6DACD7-B387-417F-9DD5-826942950FED

Q33380002-4DB59BA5-448B-43B4-A1FF-38EEA4AB767C

Q33380002-727383F3-E935-499A-80D7-CD613D4020E3

Q33380002-76002E04-06DF-41CB-9398-973D50F82BA3

Q33380002-77DFD767-3091-403C-9BE3-724145BC470C

Q33380002-8236227B-1980-41C7-9FCB-30D49E88685D

Q33380002-960FFEEA-A1FB-4436-A726-58DE8F8FA2C6

Q33380002-C2DBE96B-F492-4A8C-8847-FB623A8E1980

P2860

Q33380002-0373572A-D8B4-4453-B130-6D2AC7F1DEA3

Q33380002-1576A709-0131-4596-91D4-FBA3F96853FF

Q33380002-1CDF41CA-57FC-4C6D-8278-6B4B64528A44

Q33380002-24D2F08F-568F-46DD-85FF-D9FA16BDE8D4

Q33380002-3B12FA7C-3BE9-4B58-B332-CEBB2F20614F

Q33380002-46CB362C-1F93-4190-8F60-278CD0A542C8

Q33380002-50CAD37F-8403-4D5E-95E6-D58506048171

Q33380002-64C97219-2D12-4FB7-AFB8-EF42CC2C8E4D

Q33380002-6E33B5D6-0716-40EE-94FA-33297B38B30F

Q33380002-7E93BA55-4493-41C8-AAF1-2B8231572214

P304

Q33380002-4804264F-7500-44FF-82CB-A8B0B9017B6F

P31

Q33380002-60928E2A-8495-42BB-B5C9-BA7D6AA92F4D

P356

Q33380002-E7B80C59-EFC9-47CA-8E22-778B01CB854F

P433

Q33380002-D4E41D20-9FE3-40C1-96AA-7BA4CF49EDDC

P478

Q33380002-1F1FF268-33AA-44A5-9E02-2EA50AB4D6B4

P577

Q33380002-8FDEF501-2CB0-4471-8EF6-6D4A3887E405

P5875

Q33380002-4EDC856A-9FCE-4056-A7F2-67CEB98413B7

P698

Q33380002-5A7FD0EF-7181-4136-B6A5-56B5A7BFE712

P921

Q33380002-4CB67E03-7C9C-4D96-BA69-CB0C3E013E8C

Q33380002-644017FD-61C8-4760-83C4-D1F8FB9ED630

Q33380002-B360D7D4-5F70-4FCD-8C0A-D436D8CFAE28

P356

P1433

Annals of Oncology

P1476

Randomized phase III study com ...... h or esophagogastric junction.

@en

P2093

C Barone

http://www.w3.org/2001/XMLSchema#string

C Peschel

http://www.w3.org/2001/XMLSchema#string

E Goker

http://www.w3.org/2001/XMLSchema#string

J Zaluski

http://www.w3.org/2001/XMLSchema#string

K Wang

http://www.w3.org/2001/XMLSchema#string

L Cisar

http://www.w3.org/2001/XMLSchema#string

M Dank

http://www.w3.org/2001/XMLSchema#string

M Wenczl

http://www.w3.org/2001/XMLSchema#string

R Bugat

http://www.w3.org/2001/XMLSchema#string

S Yalcin

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.

Capecitabine as adjuvant treatment for stage III colon cancer.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.

Patterns of initial recurrence in completely resected gastric adenocarcinoma.

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

P304

1450-1457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDN166

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5297403

http://www.w3.org/2001/XMLSchema#string

P698

18558665

http://www.w3.org/2001/XMLSchema#string

P921